Global pharma firms increase China spend

Companies foster partnerships with domestic startups, set up more R&D hubs

Global pharmaceutical, medical devices and consumer goods giant Johnson & Johnson will increase investment in China, as well as strengthen cooperation with local startups, to enhance innovation and deliver better medication to more patients in China, according to a senior official of the company.

Experts said such a move is in line with China's ascent toward the higher end of the medicine industry chain, especially in the biotech sector, and also reflects the country's improving regulatory and business environment.